MEDINOTEC INC (MDNC) Financials
Newest figures come from the 10-Q for Q1 FY2027, filed Jul 9, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MDNC SEC filings page.
MEDINOTEC INC (MDNC) reported $9.7M in revenue for fiscal year 2026, up 6.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Positive earnings now depend more on operating-cost control than on demand growth or gross-margin expansion.
From FY2025 to FY2026, revenue rose6.8% while gross margin stayed near53.0% , so the core gross-profit structure was broadly stable. Yet operating margin compressed from35.0% to11.3% as net income fell, indicating expense absorption—not weaker unit economics—drove the earnings reset.
FY2026 operating cash flow of
Debt-to-equity fell from 0.6x to 0.2x by FY2026, showing reduced reliance on liabilities relative to equity. Current ratio also rose from 4.3x to 5.8x, so short-term asset coverage improved alongside deleveraging; the balance-sheet strengthening was broader than a single liquidity measure.
Financial Health Signals
MEDINOTEC INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
MEDINOTEC INC passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, MEDINOTEC INC generates $1.14 in operating cash flow ($907K OCF vs $795K net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
MEDINOTEC INC earns $12.50 in operating income for every $1 of interest expense ($1.1M vs $88K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
MEDINOTEC INC generated $2.7M in revenue in Q1 2027. This represents an increase of 24.2% from the same quarter a year earlier. Against the prior quarter it is up 45.5%.
MEDINOTEC INC's EBITDA was $202K in Q1 2027, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 29.1% from the same quarter a year earlier. Against the prior quarter it is up 198.1%.
MEDINOTEC INC reported $222K in net income in Q1 2027. This represents an increase of 95.1% from the same quarter a year earlier. Against the prior quarter it is up 420.6%.
Not reported for Q1 2027.
Cash & Balance Sheet
MEDINOTEC INC recorded an outflow of $216K in free cash flow in Q1 2027, representing a cash shortfall after capex.
MEDINOTEC INC held $2.5M in cash as of Q1 2027; long-term debt is not reported for that period.
Not reported for Q1 2027.
Margins & Returns
MEDINOTEC INC's gross margin was 49.3% in Q1 2027, indicating the percentage of revenue retained after direct costs. This is up 6.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.8 percentage points.
MEDINOTEC INC's operating margin was 6.8% in Q1 2027, reflecting core business profitability. This is down 6.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 21.3 percentage points.
MEDINOTEC INC's net profit margin was 8.4% in Q1 2027, showing the share of revenue converted to profit. This is up 3.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 12.2 percentage points.
MEDINOTEC INC's ROE was 3.8% in Q1 2027, measuring profit generated per dollar of shareholder equity. This is up 1.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.0 percentage points.
Capital Allocation
MEDINOTEC INC invested $8K in research and development in Q1 2027. This represents a decrease of 83.7% from the same quarter a year earlier. Against the prior quarter it is down 69.7%.
MEDINOTEC INC invested $40K in capex in Q1 2027, funding long-term assets and infrastructure.
Not reported for Q1 2027.
MDNC Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.7M+24.2% | $1.8M-47.8% | $2.5M-1.1% | $3.2M+79.4% | $2.1M+70.5% | $3.5M+55.2% | $2.6M+28.1% | $1.8M+414.3% |
| Cost of Revenue | $1.3M+10.0% | $955K-61.0% | $1.2M-21.9% | $1.2M+27.2% | $1.2M+287.4% | $2.5M+166.6% | $1.5M+33.9% | $971K+1491.5% |
| Gross Profit | $1.3M+43.2% | $867K-63.0% | $1.3M+29.3% | $2.0M+140.2% | $913K+52.1% | $2.3M+141.4% | $1.0M+20.5% | $833K+187.6% |
| R&D Expenses | $8K-83.7% | $26K-24.8% | $8K-88.0% | $66K+3400.8% | $49K+227.2% | $35K+0.8% | $69K+2439.2% | $2K-84.0% |
| SG&A Expenses | $594K+6.6% | $599K-32.9% | $435K+14.8% | $725K+105.0% | $557K+301.1% | $893K+140.8% | $379K-31.3% | $354K+93.0% |
| Operating Income | $181K-34.8% | -$264K-113.5% | $553K+4.8% | $529K+21.3% | $277K+3.1% | $2.0M+696.1% | $527K+104.5% | $436K+681.8% |
| EBITDA | $202K-29.1% | -$206K-110.5% | $560K+2.5% | $536K+17.7% | $285K-2.5% | $2.0M+575.8% | $547K+102.8% | $455K+568.2% |
| Interest Expense | $7K-78.5% | $8K-70.3% | $7K-83.6% | $40K-14.5% | $32K-45.0% | $28K+137.7% | $43K+165.0% | $47K+166.5% |
| Income Tax | N/A | -$631K+49.6% | $14K-90.9% | $194K+75.2% | $149K+17.4% | -$1.3M-448.3% | $149K+136.4% | $111K+799.8% |
| Net Income | $222K+95.1% | -$69K-104.7% | $403K+30.0% | $347K+21.7% | $114K+30.5% | $1.5M+1398.8% | $310K+163.0% | $285K+958.6% |
| EPS (Basic) | $0.02+100.0% | $0.00-100.0% | $0.030.0% | $0.03+50.0% | $0.010.0% | $0.12+1100.0% | $0.03+175.0% | $0.02 |
| EPS (Diluted) | N/A | N/A | N/A | $0.03+50.0% | $0.010.0% | N/A | N/A | $0.02 |
Not reported in any period shown, so not listed: Diluted Shares (Avg).
MDNC Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.0M-5.7% | $6.8M+0.1% | $6.9M+27.8% | $6.4M+20.3% | $7.4M+71.3% | $6.8M+41.7% | $5.4M+34.3% | $5.3M+7.4% |
| Current Assets | $6.6M-5.5% | $6.4M-0.1% | $6.5M+31.6% | $6.0M+22.0% | $7.0M+76.8% | $6.4M+46.7% | $4.9M+36.9% | $4.9M+27.9% |
| Cash & Equivalents | $2.5M+29.1% | $2.8M-0.5% | $2.9M+6.7% | $2.2M-18.5% | $2.0M-22.6% | $2.8M-1.4% | $2.7M-0.1% | $2.8M-2.8% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $867K+32.3% | $979K+33.7% | $921K-20.8% | $742K-42.2% | $655K-31.6% | $732K+28.4% | $1.2M+133.1% | $1.3M+1497.2% |
| Accounts Receivable | $2.5M-35.3% | $2.4M-10.0% | $2.3M+127.7% | $2.6M+233.9% | $3.9M+983.6% | $2.6M+343.0% | $992K+1201.9% | $771K+328.2% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $1.1M-62.7% | $1.1M-56.6% | $1.4M-46.7% | $1.5M-44.5% | $3.0M+46.5% | $2.5M-3.8% | $2.5M+32.4% | $2.8M+17.1% |
| Current Liabilities | $1.1M-45.9% | $1.1M-26.8% | $1.4M-8.3% | $1.5M-2.0% | $2.1M+171.0% | $1.5M+81.9% | $1.5M+338.7% | $1.6M+1164.1% |
| Non-Current Liabilities | $494-99.9% | $501-100.0% | $452-100.0% | $443-100.0% | $944K-27.4% | $1.0M-42.9% | $1.1M-32.8% | $1.2M-46.4% |
| Total Equity | $5.9M+34.0% | $5.7M+33.7% | $5.5M+94.6% | $4.8M+91.2% | $4.4M+94.2% | $4.3M+97.1% | $2.8M+36.2% | $2.5M-1.5% |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt, Retained Earnings.
MDNC Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$176K+76.8% | -$121K-222.2% | $563K+352.3% | $1.2M+199.6% | -$759K-408.4% | $99K+213.5% | $125K-67.4% | $408K+6347.0% |
| Depreciation & Amortization | $21K+183.5% | $58K+8959.1% | $8K-60.1% | $7K-61.6% | $8K-67.7% | -$657-102.0% | $19K+65.5% | $20K+57.4% |
| Capital Expenditures | $40K | N/A | N/A | N/A | N/A | -$1K-4.1% | $73K | $24K |
| Free Cash Flow | -$216K | N/A | N/A | N/A | N/A | $97K+210.2% | $52K | $385K |
| Investing Cash Flow | -$40K | N/A | N/A | N/A | N/A | $1K-87.7% | -$73K | -$12K |
| Financing Cash Flow | N/A | $25+100.0% | -$3K+97.7% | -$943K-390.1% | -$38K+93.0% | -$51K-118.6% | -$110K+79.8% | -$192K-204.9% |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
MDNC Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 49.3%+6.5pp | 47.6%-19.5pp | 53.1%+12.5pp | 61.9%+15.7pp | 42.8%-5.2pp | 67.1%+24.0pp | 40.6%-2.6pp | 46.2%-36.4pp |
| Operating Margin | 6.8%-6.2pp | -14.5%-70.6pp | 21.8%+1.2pp | 16.3%-7.8pp | 13.0%-8.5pp | 56.1%+45.2pp | 20.6%+7.7pp | 24.1%+8.3pp |
| Net Margin | 8.4%+3.0pp | -3.8%-46.1pp | 15.9%+3.8pp | 10.7%-5.1pp | 5.3%-1.6pp | 42.3%+37.9pp | 12.1%+36.7pp | 15.8%+25.2pp |
| Return on Equity | 3.8%+1.2pp | -1.2%-35.8pp | 7.3%-3.6pp | 7.2%-4.1pp | 2.6%-1.3pp | 34.6%+30.0pp | 11.0%+34.7pp | 11.3%+12.6pp |
| Return on Assets | 3.2%+1.6pp | -1.0%-22.7pp | 5.9%+0.1pp | 5.4%+0.1pp | 1.5%-0.5pp | 21.7%+19.7pp | 5.8%+18.1pp | 5.4%+6.0pp |
| Current Ratio | 5.81+2.5x | 5.83+1.6x | 4.79+1.5x | 3.90+0.8x | 3.33-1.8x | 4.27-1.0x | 3.34-7.4x | 3.13-27.8x |
| Debt-to-Equity | 0.19-0.5x | 0.19-0.4x | 0.25-0.7x | 0.32-0.8x | 0.69-0.2x | 0.59-0.6x | 0.900.0x | 1.09+0.2x |
| Asset Turnover | 0.38+0.1x | 0.27-0.2x | 0.37-0.1x | 0.51+0.2x | 0.290.0x | 0.510.0x | 0.480.0x | 0.34+0.3x |
| FCF Margin | -8.2% | N/A | N/A | N/A | N/A | 2.8%+6.7pp | 2.0% | 21.3% |
Where MEDINOTEC INC Ranks
Frequently Asked Questions
What is MEDINOTEC INC's annual revenue?
MEDINOTEC INC (MDNC) reported $9.7M in total revenue for fiscal year 2026. This represents a 6.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is MEDINOTEC INC's revenue growing?
MEDINOTEC INC (MDNC) revenue grew by 6.8% year-over-year, from $9.1M to $9.7M in fiscal year 2026.
Is MEDINOTEC INC profitable?
Yes, MEDINOTEC INC (MDNC) reported a net income of $795K in fiscal year 2026, with a net profit margin of 8.2%.
What is MEDINOTEC INC's EBITDA?
MEDINOTEC INC (MDNC) had EBITDA of $1.2M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
What is MEDINOTEC INC's gross margin?
MEDINOTEC INC (MDNC) had a gross margin of 52.7% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
What is MEDINOTEC INC's operating margin?
MEDINOTEC INC (MDNC) had an operating margin of 11.3% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.
What is MEDINOTEC INC's net profit margin?
MEDINOTEC INC (MDNC) had a net profit margin of 8.2% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.
What is MEDINOTEC INC's return on equity (ROE)?
MEDINOTEC INC (MDNC) has a return on equity of 13.9% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is MEDINOTEC INC's free cash flow?
MEDINOTEC INC (MDNC) generated $905K in free cash flow during fiscal year 2026. This represents a 14.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is MEDINOTEC INC's operating cash flow?
MEDINOTEC INC (MDNC) generated $907K in operating cash flow during fiscal year 2026, representing cash generated from core business activities.
What are MEDINOTEC INC's total assets?
MEDINOTEC INC (MDNC) had $6.8M in total assets as of fiscal year 2026, including both current and long-term assets.
What are MEDINOTEC INC's capital expenditures?
MEDINOTEC INC (MDNC) invested $1K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
How much does MEDINOTEC INC spend on research and development?
MEDINOTEC INC (MDNC) invested $150K in research and development during fiscal year 2026.
What is MEDINOTEC INC's current ratio?
MEDINOTEC INC (MDNC) had a current ratio of 5.83 as of fiscal year 2026, which is generally considered healthy.
What is MEDINOTEC INC's debt-to-equity ratio?
MEDINOTEC INC (MDNC) had a debt-to-equity ratio of 0.19 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is MEDINOTEC INC's return on assets (ROA)?
MEDINOTEC INC (MDNC) had a return on assets of 11.7% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is MEDINOTEC INC's Piotroski F-Score?
MEDINOTEC INC (MDNC) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are MEDINOTEC INC's earnings high quality?
MEDINOTEC INC (MDNC) has an earnings quality ratio of 1.14x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can MEDINOTEC INC cover its interest payments?
MEDINOTEC INC (MDNC) has an interest coverage ratio of 12.50x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.